Article Information
History
- July 3, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 3, 2021 - 17:12).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Francesca Rovida1,
- Irene Cassaniti1,
- Stefania Paolucci1,
- Elena Percivalle1,
- Antonella Sarasini1,
- Antonio Piralla1,
- Federica Giardina1,
- Jose Camilla Sammartino1,
- Alessandro Ferrari1,
- Federica Bergami1,
- Alba Muzzi2,
- Viola Novelli2,
- Alessandro Meloni2,6,
- Anna Maria Grugnetti3,
- Giuseppina Grugnetti3,
- Claudia Rona2,
- Marinella Daglio2,
- Carlo Marena2,
- Antonio Triarico4,
- Daniele Lilleri1,* and
- Fausto Baldanti1,5
- 1Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 2Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 3Health Professions Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 4Direzione Sanitaria, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 5Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
- 6Department of Public Health, Experimental and Forensic Medicine, Section of Hygiene, University of Pavia, Pavia, Italy
- ↵*Correspondence to: Daniele Lilleri; d.lilleri{at}smatteo.pv.it
Posted July 03, 2021.
SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted
